Heliyon (Mar 2024)

Case report of pediatric TTMV-related acute promyelocytic leukemia with central nervous system infiltration and rapid accumulation of RARA-LBD mutations

  • Linya Wang,
  • Jiaqi Chen,
  • Bei Hou,
  • Ying Wu,
  • Jun Yang,
  • Xiaosu Zhou,
  • Qihui Chen,
  • Xue Chen,
  • Yang Zhang,
  • Fang Wang,
  • Jiancheng Fang,
  • Panxiang Cao,
  • Mingyue Liu,
  • Yanan Li,
  • Pan Zhang,
  • Yan Liu,
  • Ruidong Zhang,
  • Hongxing Liu,
  • Huyong Zheng

Journal volume & issue
Vol. 10, no. 5
p. e27107

Abstract

Read online

TTMV::RARA is a recently reported fusion gene associated with acute promyelocytic leukemia (APL), caused by the integration of torque teno mini virus (TTMV) genomic fragments into the second intron of the RARA gene. Currently, there have been only six documented cases, with clinical presentations showing significant variability. Although initial responses to all-trans retinoic acid (ATRA) treatment may be observed in patients with TTMV::RARA-APL, the overall prognosis remains unfavorable among infrequent reported cases. This article presents a pediatric case that manifested as PML::RARA-negative APL with central nervous system involvement at onset. The patient experienced both intramedullary and extramedullary relapse one year after undergoing allogeneic hematopoietic stem cell transplantation. Upon identification as TTMV::RARA-APL and subsequent administration of two rounds of ATRA-based treatment, the patient rapidly developed multiple RARA ligand-binding domain mutations and demonstrated extensive resistance to ATRA and various other therapeutic interventions. Additionally, the patient experienced ARID1A mutant clone expansion and progressed MYC-targeted gene activation. This case represents the first documentation of extramedullary involvement at both the initial diagnosis and relapse stages, emphasizing the intricate clinical features and challenges associated with the rapid accumulation of multiple ATRA-resistant mutations in TTMV::RARA-APL, characterizing it as a distinct and complex sub-entity of atypical APL.

Keywords